Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need.
Excellent balance sheet and overvalued.
Share Price & News
How has Mersana Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 0M4's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 0M4 exceeded the German Biotechs industry which returned -10.6% over the past year.
Return vs Market: 0M4 exceeded the German Market which returned -20.4% over the past year.
Price Volatility Vs. Market
How volatile is Mersana Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Mersana Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 0M4's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 0M4's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 0M4 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 0M4 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 0M4's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 0M4 is good value based on its PB Ratio (3.1x) compared to the DE Biotechs industry average (3.5x).
How is Mersana Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0M4 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0M4 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0M4 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0M4's revenue is expected to decline over the next 3 years (-82.2% per year).
High Growth Revenue: 0M4's revenue is forecast to decline over the next 3 years (-82.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0M4 is forecast to be unprofitable in 3 years.
How has Mersana Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 0M4 is currently unprofitable.
Growing Profit Margin: 0M4 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 0M4 is unprofitable, and losses have increased over the past 5 years at a rate of -21% per year.
Accelerating Growth: Unable to compare 0M4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0M4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: 0M4 has a negative Return on Equity (-36.02%), as it is currently unprofitable.
How is Mersana Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 0M4's short term assets ($101.3M) exceed its short term liabilities ($24.1M).
Long Term Liabilities: 0M4's short term assets ($101.3M) exceed its long term liabilities ($5.2M).
Debt to Equity History and Analysis
Debt Level: 0M4's debt to equity ratio (6.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 0M4's debt to equity ratio has reduced over the past 5 years.
Inventory Level: 0M4 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 0M4's debt is covered by short term assets (assets are 20.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0M4 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0M4 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -52.1% each year.
What is Mersana Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 0M4's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 0M4's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 0M4's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 0M4's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 0M4's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Anna Protopapas (55yo)
Ms. Anna Protopapas has been the Chief Executive Officer and President of Mersana Therapeutics, Inc. since March 2015. Ms. Protopapas has extensive strategic leadership experience and a demonstrated track ...
CEO Compensation Analysis
Compensation vs Market: Anna's total compensation ($USD2.61M) is above average for companies of similar size in the German market ($USD730.07K).
Compensation vs Earnings: Anna's compensation has increased whilst the company is unprofitable.
|Chief Science & Technology Officer||1.25yrs||US$1.05m||0.027% $60.3k|
|Co-Founder||no data||no data||no data|
|Senior Vice President of Finance & Product Strategy||0.75yr||no data||no data|
|VP, Controller & Principal Accounting Officer||0.58yr||no data||no data|
|Executive Director of Investor Relations & Corporate Communications||1.42yrs||no data||no data|
|Vice President of Legal Operations||no data||no data||no data|
|Chief Business Officer & Company Secretary||6.42yrs||no data||no data|
|Senior Vice President of Chemistry||4.17yrs||no data||no data|
|Chief Medical Officer||1.42yrs||no data||no data|
Experienced Management: 0M4's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
|Independent Chairman||7.75yrs||US$160.44k||no data|
|Independent Director||2.58yrs||US$136.43k||no data|
|Independent Director||2.08yrs||US$261.55k||no data|
|Independent Director||3.67yrs||US$122.43k||no data|
|Independent Director||3.25yrs||US$126.41k||no data|
|Board Observer||no data||no data||no data|
Experienced Board: 0M4's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 88.8%.
Mersana Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Mersana Therapeutics, Inc.
- Ticker: 0M4
- Exchange: DB
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$238.053m
- Listing Market Cap: US$220.651m
- Shares outstanding: 45.43m
- Website: https://www.mersana.com
Number of Employees
- Mersana Therapeutics, Inc.
- 840 Memorial Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MRSN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2017|
|0M4||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2017|
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 04:02|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.